No tax




Security policy (edit with Customer reassurance module)


Delivery policy (edit with Customer reassurance module)


Return policy (edit with Customer reassurance module)

Modified Release Coated Tablets


1 pill contains Trimetazidine dihydrochloride 35 mg;
Excipients: Calcium hydrogen phosphate dihydrate, methylhydroxypropylcellulose, povidone, colloidal silicon anhydride, Magnesium stearate, titanium dioxide, glycerol, macrogol 6000, iron oxide red.


60 pcs.

Mechanism of action

Preductal MV is an antianginal drug. Normalizes the energy metabolism of cells subjected to hypoxia or ischemia, prevents a decrease in the intracellular content of ATP. Thus, the drug ensures the normal functioning of membrane ion channels, transmembrane transfer of potassium and sodium ions and the preservation of cellular homeostasis.
Trimetazidine slows down the oxidation of fatty acids by selectively inhibiting long-chain 3-ketoacetyl-CoA thiolase, which leads to an increase in glucose oxidation and to the restoration of the conjugation between glycolysis and oxidative decarboxylation and, as has been shown, causes myocardial protection from ischemia. Switching fatty acid oxidation to glucose oxidation underlies the antianginal action of trimetazidine.
Experimental studies on animals have shown that trimetazidine supports the energy metabolism of the heart and neurosensory organs during periods of ischemic episodes; reduces the amount of intracellular acidosis and the degree of changes in the transmembrane ion flux that occurs during ischemia; reduces the level of migration and infiltration of polynuclear neutrophils in ischemic and reperfusional tissues of the heart, reduces the size of myocardial damage; it does not affect hemodynamics.
In clinical studies, it was shown that in patients with coronary artery disease (including angina), the drug increases the coronary reserve, thereby slowing the development of ischemia caused by exercise, starting from the 15th day of therapy; It limits the sharp fluctuations in blood pressure without any significant changes in heart rate. Preductal reduces the frequency of strokes, significantly reduces the need for taking Nitroglycerin.

Indications and usage

- long-term treatment of coronary artery disease: prevention of strokes (monotherapy or as part of combination therapy);
- treatment of cochleo-vestibular disorders of ischemic nature (such as dizziness, tinnitus, hearing impairment);
- chorioretinal vascular disorders with ischemic component.


Pregnancy; breastfeeding, hypersensitivity to the drug, age up to 18 years.

Dosage and administration

Preductal MV is prescribed at 35 mg (1 tab.) 2 times a day (morning and evening). Daily dose - 70 mg (2 tablets.). The duration of therapy is set individually.
The drug is taken with food.

Adverse reactions

Gastrointestinal: rarely - nausea, vomiting.
Allergic reactions: skin rash, itching and other manifestations are possible.

38 Items